HaugenBR, KaneMA. 2010. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab, 95:987–993.
4.
XingM. 2010. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid, 20:697–706.
5.
KnaufJA, FaginJA. 2009. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets. Curr Opin Cell Biol, 21:296–303.
6.
NikiforovaMN, LynchRA, BiddingerPW, AlexanderEK, DornGW2nd, TalliniG, KrollTG, NikiforovYE. 2003. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab, 88:2318–2326.
7.
VaskoV, FerrandM, Di CristofaroJ, CarayonP, HenryJF, de MiccoC. 2003. Specific pattern of RAS oncogene mutations in follicular thyroid tumors. J Clin Endocrinol Metab, 88:2745–2752.
8.
CantaraS, CapezzoneM, MarchisottaS, CapuanoS, BusoneroG, TotiP, Di SantoA, CarusoG, CarliAF, BrilliL, MontanaroA, PaciniF. 2010. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab, 95:1365–1369.
9.
HouP, LiuD, ShanY, HuS, StudemanK, CondourisS, WangY, TrinkA, El-NaggarAK, TalliniG, VaskoV, XingM. 2007. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res, 13:1161–1170.
10.
Ricarte-FilhoJC, RyderM, ChitaleDA, RiveraM, HeguyA, LadanyiM, JanakiramanM, SolitD, KnaufJA, TuttleRM, GhosseinRA, FaginJA. 2009. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA and AKT1. Cancer Res, 69:4885–4893.
11.
LiuZ, HouP, JiM, GuanH, StudemanK, JensenK, VaskoV, El-NaggarAK, XingM. 2008. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab, 93:3106–3116.
12.
Garcia-RostanG, CostaAM, Pereira-CastroI, SalvatoreG, HernandezR, HermsemMJ, HerreroA, FuscoA, Cameselle-TeijeiroJ, SantoroM. 2005. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res, 65:10199–10207.
13.
SantarpiaL, El-NaggarAK, CoteGJ, MyersJN, ShermanSI. 2008. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab, 93:278–284.
14.
SajiM, RingelMD. 2010. The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol, 321:20–28.
15.
LiuD, XingM. 2008. Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid, 18:853–864.
16.
LiuD, XingJ, TrinkB, XingM. 2010. BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer, 127:2965–2973.
17.
JinN, JiangT, RosenDM, NelkinBD, BallDW. 2009. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab, 94:4107–4112.
18.
MillerKA, YeagerN, BakerK, LiaoXH, RefetoffS, Di CristofanoA. 2009. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. Cancer Res, 69:3689–3694.
19.
VitaglianoD, PortellaG, TronconeG, FrancioneA, RossiC, BrunoA, GiorginiA, ColuzziS, NappiTC, RothsteinJL, PasquinelliR, ChiappettaG, TerraccianoD, MacchiaV, MelilloRM, FuscoA, SantoroM. 2006. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene, 25:5467–5474.
20.
FeunteunJ, MichielsF, RochefortP, CaillouB, TalbotM, FournesB, MerckenL, SchlumbergerM, MonierR. 1997. Targeted oncogenesis in the thyroid of transgenic mice. Horm Res, 47:137–139.
HingoraniSR, PetricoinEF, MaitraA, RajapakseV, KingC, JacobetzMA, RossS, ConradsTP, VeenstraTD, HittBA, KawaguchiY, JohannD, LiottaLA, CrawfordHC, PuttME, JacksT, WrightCV, HrubanRH, LowyAM, TuvesonDA. 2003. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4:437–450.
23.
HaigisKM, KendallKR, WangY, CheungA, HaigisMC, GlickmanJN, Niwa-KawakitaM, Sweet-CorderoA, Sebolt-LeopoldJ, ShannonKM, SettlemanJ, GiovanniniM, JacksT. 2008. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet, 40:600–608.
24.
JacksonEL, WillisN, MercerK, BronsonRT, CrowleyD, MontoyaR, JacksT, TuvesonDA. 2001. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev, 15:3243–3248.
MacraeM, NeveRM, Rodriguez-VicianaP, HaqqC, YehJ, ChenC, GrayJW, McCormickF. 2005. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell, 8:111–118.
27.
ShawAT, MeissnerA, DowdleJA, CrowleyD, MagendantzM, OuyangC, ParisiT, RajagopalJ, BlankLJ, BronsonRT, StoneJR, TuvesonDA, JaenischR, JacksT. 2007. Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis. Genes Dev, 21:694–707.
28.
SansomOJ, MenielV, WilkinsJA, ColeAM, OienKA, MarshV, JamiesonTJ, GuerraC, AshtonGH, BarbacidM, ClarkeAR. 2006. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci USA, 103:14122–14127.
29.
KnaufJA, MaX, SmithEP, ZhangL, MitsutakeN, LiaoXH, RefetoffS, NikiforovYE, FaginJA. 2005. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res, 65:4238–4245.
KaneshigeM, KaneshigeK, ZhuX, DaceA, GarrettL, CarterTA, KazlauskaiteR, PankratzDG, Wynshaw-BorisA, RefetoffS, WeintraubB, WillinghamMC, BarlowC, ChengS. 2000. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc Natl Acad Sci USA, 97:13209–13214.
32.
SuzukiH, WillinghamMC, ChengSY. 2002. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid, 12:963–969.
33.
HoltK, KassonB, PessinJ. 1996. Insulin stimulation of MEK-dependent but ERK-independent SOS protein kinase. Mol. Cell. Biol., 16:577–583.
34.
KolchW. 2005. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol, 6:827–837.
35.
KennedyAL, MortonJP, ManoharanI, NelsonDM, JamiesonNB, PawlikowskiJS, McBryanT, DoyleB, McKayC, OienKA, EndersGH, ZhangR, SansomOJ, AdamsPD. 2011. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell, 42:36–49.
36.
EngelmanJA, ChenL, TanX, CrosbyK, GuimaraesAR, UpadhyayR, MairaM, McNamaraK, PereraSA, SongY, ChirieacLR, KaurR, LightbownA, SimendingerJ, LiT, PaderaRF, Garcia-EcheverriaC, WeisslederR, MahmoodU, CantleyLC, WongKK. 2008. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med, 14:1351–1356.
37.
HillR, CalvopinaJH, KimC, WangY, DawsonDW, DonahueTR, DryS, WuH. 2010. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res, 70:7114–7124.
38.
HollandEC, CelestinoJ, DaiC, SchaeferL, SawayaRE, FullerGN. 2000. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet, 25:55–57.
39.
KimTH, WangJ, LeeKY, FrancoHL, BroaddusRR, LydonJP, JeongJW, DemayoFJ. 2010. The synergistic effect of conditional Pten loss and oncogenic K-ras mutation on endometrial cancer development occurs via decreased progesterone receptor action. J Oncol, 2010:139087.
40.
DimaM, MillerKA, Antico-ArciuchVG, Di CristofanoA. 2011. Establishment and characterization of cell lines from a novel mouse model of poorly differentiated thyroid carcinoma: powerful tools for basic and preclinical research. Thyroid, 21:1001–1007.
41.
SchweppeRE, KlopperJP, KorchC, PugazhenthiU, BenezraM, KnaufJA, FaginJA, MarlowL, CoplandJA, SmallridgeRC, HaugenBR. 2008. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab, 93:4331–4341.
